AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie income Statement — Net revenues ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Earnings (DB)
Latest, FY2025
61,160
Period ended Dec 31, 2025
Change on a year earlier
+8.6%
56,334 in FY2024
History
15 years
Since FY2011
Sources
13
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Income Statement — Net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 61,160 | +8.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 56,334 | +3.7% | Form 10-K (filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 54,318 | -6.4% | Form 10-K (filed 2024-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 58,054 | +3.3% | Form 10-K (filed 2023-02-17) ↗ |
| FY2021 | Dec 31, 2021 | 56,197 | +22.7% | Form 10-K (filed 2022-02-18) ↗ |
| FY2020 | Dec 31, 2020 | 45,804 | +37.7% | Form 10-K (filed 2021-02-19) ↗ |
| FY2019 | Dec 31, 2019 | 33,266 | +1.6% | Form 10-K (filed 2020-02-21) ↗ |
| FY2018 | Dec 31, 2018 | 32,753 | +16.1% | Form 10-K (filed 2019-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 28,216 | +10.1% | Form 10-K (filed 2018-02-16) ↗ |
| FY2016 | Dec 31, 2016 | 25,638 | +12.2% | Form 10-K (filed 2017-02-17) ↗ |
| FY2015 | Dec 31, 2015 | 22,859 | +14.5% | Form 10-K (filed 2016-02-19) ↗ |
| FY2014 | Dec 31, 2014 | 19,960 | +6.2% | Form 10-K (filed 2015-02-20) ↗ |
| FY2013 | Dec 31, 2013 | 18,790 | +2.2% | Form 10-K (filed 2014-02-21) ↗ |
| FY2012 | Dec 31, 2012 | 18,380 | +5.4% | Form 10-K (filed 2014-02-21) ↗ |
| FY2011 | Dec 31, 2011 | 17,444 | – | Form 10-K (filed 2014-02-21) ↗ |
Breakdown
What makes up income statement — net revenues ($m)
- Cost of products sold ($M)18,204 · FY2025
- Total operating costs and expenses ($M)46,085 · FY2025
- Selling, general and administrative expense ($M)14,010 · FY2025
- Research and development expense ($M)9,096 · FY2025
- Operating earnings ($M)15,075 · FY2025
- Interest expense ($M)2,893 · FY2025
- Interest income ($M)266 · FY2025
- Earnings before income tax ($M)6,597 · FY2025
- Income tax expense ($M)2,364 · FY2025
- Net earnings attributable to AbbVie Inc. ($M)4,186 · FY2025
- Earnings per share — Basic ($/sh)2.37 · FY2025
- Earnings per share — Diluted ($/sh)2.36 · FY2025
- Weighted-average basic shares outstanding (M)1,769.00 · FY2025
- Weighted-average diluted shares outstanding (M)1,773.00 · FY2025
Cite this data
StockData. (2026). AbbVie Income Statement — Net revenues ($M) ($M), annual FY2011–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/fs_income_stmt
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.